Literature DB >> 2525515

Disomic homozygosity in 21-trisomic cells: a mechanism responsible for transient myeloproliferative syndrome.

K Abe1, T Kajii, N Niikawa.   

Abstract

Nine patients with transient myeloproliferative syndrome (TMS) with or without Down syndrome (DS) phenotype were studied cytogenetically, particularly with regard to the origin of trisomy 21. Of six DS patients, five had standard trisomy 21 and one a mosaic consisting of 21-tetrasomic, trisomic and disomic cell lines. The other three non-DS patients were mosaics with both 21-trisomic and -disomic cell lines. In all nine patients, the leukemoid cells in TMS stage were largely or exclusively composed of trisomy or tetrasomy 21, an indication that the additional chromosome(s) 21 plays an important role in the occurrence of TMS. Sequential Q- and R-banding analysis of heteromorphisms demonstrated that all these patients had a duplication of a chromosome 21, as revealed by an "aab" pattern, regardless of DS or normal phenotype or parental origin of the extra chromosome 21. Irrespective of the possibility of recombination, the "aa" chromosomes are homozygous, i.e. show disomic homozygosity: this may in turn result in the duplication of a gene that controls the proliferation of the myelogenous cells, thereby leading to TMS.

Entities:  

Mesh:

Year:  1989        PMID: 2525515     DOI: 10.1007/bf00273988

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  11 in total

1.  Transient spontaneous remission in a case of untreated congenital leukemia.

Authors:  J Van Eys; J M Flexner
Journal:  Am J Dis Child       Date:  1969-09

2.  Trisomy 21 (Down syndrome): studying nondisjunction and meiotic recombination by using cytogenetic and molecular polymorphisms that span chromosome 21.

Authors:  G D Stewart; T J Hassold; A Berg; P Watkins; R Tanzi; D M Kurnit
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

3.  Neonate with Down's syndrome and transient congenital leukemia. In vitro studies.

Authors:  P C Rogers; D K Kalousek; J F Denegri; J W Thomas; M A Baker
Journal:  Am J Pediatr Hematol Oncol       Date:  1983

4.  Origin of nondisjunction in trisomy 21 syndrome: all studies compiled, parental age analysis, and international comparisons.

Authors:  R C Juberg; P N Mowrey
Journal:  Am J Med Genet       Date:  1983-09

5.  Congenital monocytic leukaemia.

Authors:  J S Lilleyman
Journal:  Clin Lab Haematol       Date:  1980

6.  The origin of mosaic Down syndrome: four cases with chromosome markers.

Authors:  N Niikawa; T Kajii
Journal:  Am J Hum Genet       Date:  1984-01       Impact factor: 11.025

7.  Leukemia with Down's syndrome: translocation between chromosomes 1 and 19 in acute myelomonocytic leukemia following transient congenital myeloproliferative syndrome.

Authors:  R Morgan; F Hecht; M L Cleary; J Sklar; M P Link
Journal:  Blood       Date:  1985-12       Impact factor: 22.113

8.  Spontaneous remission of presumed congenital acute nonlymphoblastic leukemia (ANLL) in a karyotypically normal neonate.

Authors:  B C Lampkin; J J Peipon; J K Price; K E Bove; A K Srivastava; M M Jones
Journal:  Am J Pediatr Hematol Oncol       Date:  1985

Review 9.  Small metacentric marker chromosomes, particularly isochromosomes, in cancer.

Authors:  N B Atkin; M C Baker
Journal:  Hum Genet       Date:  1988-06       Impact factor: 4.132

10.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

View more
  9 in total

1.  Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome.

Authors:  M Richards; J Welch; A Watmore; D Readett; A J Vora
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-11       Impact factor: 5.747

2.  Nondisjunction of chromosome 21: comparisons of cytogenetic and molecular studies of the meiotic stage and parent of origin.

Authors:  B J Lorber; M Grantham; J Peters; H F Willard; T J Hassold
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

3.  Disomic homozygosity and leukemia in Down's syndrome.

Authors:  R Sansone; M Pierluigi; S Carobbi; M Cominetti; P Strigini
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

4.  Possible mapping of the gene for transient myeloproliferative syndrome at 21q11.2.

Authors:  N Niikawa; H X Deng; K Abe; N Harada; T Okada; H Tsuchiya; I Akaboshi; I Matsuda; Y Fukushima; Y Kaneko
Journal:  Hum Genet       Date:  1991-09       Impact factor: 4.132

5.  Bacterial contig map of the 21q11 region associated with Alzheimer's disease and abnormal myelopoiesis in Down syndrome.

Authors:  J Groet; J H Ives; A P South; P R Baptista; T A Jones; M L Yaspo; H Lehrach; M C Potier; C Van Broeckhoven; D Nizetić
Journal:  Genome Res       Date:  1998-04       Impact factor: 9.043

6.  Leukaemia and transient leukaemia in Down syndrome.

Authors:  L Iselius; P Jacobs; N Morton
Journal:  Hum Genet       Date:  1990-10       Impact factor: 4.132

7.  Isolation of a cosmid clone corresponding to an inv(21) breakpoint of a patient with transient abnormal myelopoiesis.

Authors:  T Ohta; M Nakano; T Tsujita; K Abe; K Osoegawa; T Yamagata; K Yoshiura; Y Jinno; E Soeda; Y Nakamura; N Niikawa
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

8.  Cytogenetic and molecular studies of Down syndrome individuals with leukemia.

Authors:  J J Shen; B J Williams; A Zipursky; J Doyle; S L Sherman; P A Jacobs; A L Shugar; S W Soukup; T J Hassold
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

9.  Demographic study of leukaemia presenting within the first 3 months of life in the Northern Health Region of England.

Authors:  R P S Bajwa; R Skinner; K P Windebank; M M Reid
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.